Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AbbVie Inc. Director's Dealing 2020

May 22, 2020

29755_dirs_2020-05-22_bf2f7f86-ae82-45a5-81f9-b82775d19d15.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4/A — Form 4/A

Issuer: AbbVie Inc. (ABBV)
CIK: 0001551152
Period of Report: 2020-05-08

Reporting Person: FREYMAN THOMAS C (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-05-08 Common Stock, $0.01 par value A 2583 Acquired 117342 Direct
2020-05-08 Common Stock, $0.01 par value A 2333 Acquired 119675 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock, $0.01 par value 4000 Indirect
Common Stock, $0.01 par value 1941 Indirect
Common Stock, $0.01 par value 1941 Indirect

Footnotes

F1: Received in exchange for 2,983 shares of Allergan plc common stock in connection with its acquisition by AbbVie Inc. Allergan shareholders received 0.8660 AbbVie shares for each Allergan share (based on the closing price of AbbVie's common stock of $84.22 on May 7, 2020).

F2: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

F3: The reporting person's spouse is the trustee of the trust. The trust is revocable by his spouse. The reporting person disclaims beneficial ownership of these securities.

F4: Shares are held in an irrevocable trust for the benefit of the reporting person's son. The reporting person's spouse is the trustee of the trust. The reporting person disclaims beneficial ownership of these securities.